8-K: Indaptus Therapeutics Reports Q4 and Year-End 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics announces its Q4 and year-end 2024 financial results, highlighting clinical progress in its Decoy20 Phase 1 trial and a corporate update.

Summary

• Indaptus Therapeutics reported its financial results for the fourth quarter and fiscal year ended December 31, 2024.
• The company's Phase 1 trial of Decoy20 has enrolled over 20 patients in the weekly dosing cohort.
• Some patients in the trial are showing signs of stable disease.
• Indaptus has entered a clinical supply agreement with BeiGene to evaluate Decoy20 in combination with tislelizumab.
• The company secured new patents in China, Japan, and Israel related to Decoy bacteria compositions.
• Health Canada has authorized the expansion of clinical trial sites.
• Research and development expenses for the quarter were $2.5 million, compared to $2.0 million in the same period of 2023.
• Research and development expenses for the year were $7.2 million, compared to $7.6 million in 2023.
• General and administrative expenses for the quarter were $1.7 million, compared to $2.2 million in the same period of 2023.
• General and administrative expenses for the year were $8.1 million, compared to $8.8 million in 2023.
• Loss per share for the year was $1.61, compared to $1.83 in 2023.
• As of December 31, 2024, the company had $5.8 million in cash and cash equivalents.
• In January 2025, Indaptus completed a private placement resulting in net proceeds of $2.0 million.
• In February 2025, the company established a $20 million equity line of credit with Yorkville.
• The company expects its current cash to support operations into the second quarter of 2025.
• Net cash used in operating activities was $12.3 million for the year, compared to $13.4 million in 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's positive clinical progress and collaborations, the limited cash runway and need for potential future financing temper the outlook.

Positives

• The Phase 1 trial of Decoy20 is progressing, with over 20 patients enrolled in the weekly dosing cohort.
• Early signs of potential benefit are emerging, with some patients demonstrating stable disease.
• The clinical supply agreement with BeiGene allows for the evaluation of Decoy20 in combination with tislelizumab.
• New patents in China, Japan, and Israel expand and reinforce the company's intellectual property position.
• Clinical Trial authorization from Health Canada allows for expansion of clinical trial sites and broader patient recruitment.
• The company successfully completed multiple financings throughout the past year, bolstering financial flexibility.
• Loss per share decreased from $1.83 to $1.61 year over year.

Negatives

• The company had $5.8 million in cash and cash equivalents as of December 31, 2024, a decrease from $13.4 million at the end of 2023.
• The company expects its current cash to support operations only into the second quarter of 2025.
• Net cash used in operating activities was $12.3 million for the year.

Risks

• The company's limited cash runway may require additional financing to continue operations beyond the second quarter of 2025.
• Clinical trials are lengthy and expensive processes with uncertain outcomes.
• The company's reliance on third parties for preclinical studies, clinical trials, and manufacturing poses a risk.
• The company faces competition from other companies with product candidates that may be approved faster, marketed more effectively, and better tolerated.
• The company's ability to protect its proprietary technology is crucial for its success.

Future Outlook

The company plans to dose the first patients in its combination study with BeiGene's Tislelizumab, increase trial sites to accelerate patient enrollment, provide clinical updates throughout 2025, and nominate a new candidate for IND enabling studies.

Management Comments

• Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, 'We continue to make significant progress in our Phase 1 trial of Decoy20, and enrolling more than 20 patients in the weekly dosing cohort marks an important milestone.'
• Jeffrey Meckler also stated, 'We are particularly encouraged by the emerging clinical data, with some patients in this cohort demonstrating stable disease an early sign that Decoy20s immune-modulating approach may be having a meaningful impact.'

Industry Context

Indaptus Therapeutics is focused on immunotherapy, a rapidly growing field in cancer treatment. The collaboration with BeiGene, a major player in the PD-1 inhibitor space, is a significant step for Indaptus. The development of the Decoy platform, which targets multiple immune receptors, aligns with the industry trend of developing multi-faceted immunotherapies.

Comparison to Industry Standards

• Indaptus's approach of using attenuated bacteria to stimulate the immune system is similar to that of companies like Vaximm, which is developing oral vaccines based on attenuated bacteria to treat cancer.
• The collaboration with BeiGene to combine Decoy20 with tislelizumab is comparable to other companies combining their novel therapies with established checkpoint inhibitors like Keytruda (Merck) or Opdivo (Bristol Myers Squibb).
• The reported R&D expenses are relatively low compared to larger pharmaceutical companies, reflecting Indaptus's stage of development and focus on early-stage clinical trials.

Stakeholder Impact

• Shareholders: The clinical progress and collaborations are positive, but the limited cash runway and potential need for further financing could be concerning.
• Employees: The company's ability to continue operations and advance its pipeline depends on securing additional funding.
• Patients: The progress in the Decoy20 trial offers hope for new treatment options for advanced solid tumors.
• Partners: The collaboration with BeiGene is a positive development for both companies.

Next Steps

• Dose the first patients in the combination study with BeiGene's Tislelizumab.
• Increase the number of trial sites to accelerate patient enrollment and data collection.
• Provide further clinical updates throughout 2025, including data from weekly-dosing cohorts.
• Provide new data on expansion of the Decoy platform and nominate a new candidate for IND enabling studies.

Key Dates